Literature DB >> 26446506

Obinutuzumab in multidrug-resistant hairy cell leukemia.

Jan-Paul Bohn1, Ella Willenbacher2, Michael Steurer2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26446506     DOI： 10.1007/s00277-015-2520-y

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  4 in total

1.  Hairy Cell Leukemia Patients Have a Normal Life Expectancy-A 35-Year Single-Center Experience and Comparison with the General Population.

Authors:  Jan-Paul Bohn; Sabrina Neururer; Markus Pirklbauer; Andreas Pircher; Dominik Wolf
Journal:  Cancers (Basel)       Date:  2022-02-28       Impact factor: 6.639

2.  Long-term treatment of hairy cell leukemia with interferon-α: still a viable therapeutic option.

Authors:  Jan-Paul Bohn; Guenther Gastl; Michael Steurer
Journal:  Memo       Date:  2016-06-17

3.  Hairy cell leukemia 2018: Update on diagnosis, risk-stratification, and treatment.

Authors:  Xavier Troussard; Edouard Cornet
Journal:  Am J Hematol       Date:  2017-12       Impact factor: 10.047

4.  Successful treatment of hairy cell leukemia variant with obinutuzumab.

Authors:  Diana Al-Sarayfi; Freek O Meeuwes; Thijs Oude Munnink; Wouter Plattel; Stefano Rosati; Estella Matutes; Marcel Nijland
Journal:  Ann Hematol       Date:  2021-06-04       Impact factor: 3.673
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.